The End of the Beginning, Part 2: Reflections on Another 100 Articles

This is not the first time I've reached the 20-article mark in a series about nicotine, nor will it be the last. The nicotine landscape is vast—spanning pharmacology and psychology, economics and politics, global supply chains and individual quit attempts—and any honest exploration of it generates more questions than conclusions. What distinguishes this second journey is a deepening appreciation for a single theme that has emerged across every topic: the gap between evidence and policy. Over and over, in domain after domain, the pattern repeats. The evidence points toward a direction. The policy moves in a different direction—sometimes the opposite direction. And the gap between them, measured in years of delay and millions of preventable deaths, is where the nicotine story's tragedy and its hope both reside.

The evidence-policy gap is not mysterious. It's produced by the same structural forces that shape every domain of public health: the political power of the tobacco industry, the institutional inertia of organizations built for a different era of the epidemic, the funding structures that select for certain questions and certain answers, the psychological biases that make it easier to maintain existing beliefs than to update them, and the cultural narratives—'nicotine is evil,' 'addiction is a choice'—that constrain the range of policies that are politically viable. Understanding these forces doesn't make the gap disappear, but it makes it comprehensible. And comprehension is the first step toward action.

If there's a single policy recommendation that emerges from the research surveyed in this series, it's this: regulate nicotine products based on their risk profile, not their legal category. The current system, in most countries, treats all non-pharmaceutical nicotine products as essentially equivalent for regulatory purposes—subjecting vaping products to the same taxes, marketing restrictions, and access limits as combustible cigarettes, or even more restrictive ones. This approach is not evidence-based. It's category-based, and the categories were established in an era when cigarettes dominated the market and 'tobacco product' was a meaningful proxy for risk. In a diversified nicotine market, where products range from the catastrophically harmful (combustible cigarettes) to the minimally harmful (pharmaceutical NRT), a regulatory framework that can't distinguish between them is worse than obsolete. It's actively harmful, because it eliminates the incentives for smokers to switch to lower-risk products.

Risk-proportionate regulation is not a radical proposal. It's how we regulate virtually every other category of consumer products where different formulations have different risk profiles—vehicles, energy, food, pharmaceuticals. The anomaly is not risk-proportionate nicotine regulation. It's the absence of it. Implementing it would require differential taxation (cigarettes taxed highest, non-combustible products lower, pharmaceutical NRT lowest), honest risk communication (actively informing smokers about relative risks), product standards calibrated to risk (reduced-toxicant standards for cigarettes, quality and safety standards for non-combustible products), and retail access policies that make the lowest-risk products the most accessible. These are not speculative interventions. They're evidence-based measures that several countries have already implemented, with measurable improvements in smoking cessation and population health. The evidence exists. The policy templates exist. What's missing is the political will.

The human dimension of the nicotine story—the billion-plus smokers, the millions of vapers and pouch users, the teenagers experimenting with nicotine, the communities targeted by industry marketing—demands that we hold the complexity of their experiences in mind as we debate the policies that affect them. The smoker who's failed to quit with every approved method is not a data point in a policy model. The vaper who's dramatically reduced their disease risk is not a victim of industry manipulation (or not ONLY that). The teenager addicted to disposable vapes is not a moral failure or a policy failure—they're a person navigating a developmental stage with a brain that's exquisitely vulnerable to addictive substances, in an environment saturated with products designed to exploit that vulnerability. The policies we debate in the abstract have concrete consequences for these people. The compassion we bring to the debate—or fail to bring—shapes those consequences.

The series continues because the story continues. The evidence is still accumulating. The policies are still being debated. The products are still evolving. And the smokers are still dying—7 million annually, mostly from a product that could be largely replaced by alternatives that are dramatically less harmful. The gap between what we know and what we do remains the central tragedy of the nicotine epidemic. Closing that gap—through evidence-based policy, honest communication, and compassion for the people at the center of the story—is the unfinished business of tobacco control. This series, like the work of tobacco control itself, is not finished. It's merely at another waypoint. The next articles are waiting to be written. The evidence is waiting to be applied. The smokers are waiting to be helped. The work continues.